Genotip 1b ile infekte kronik hepatit C'li hastalarda tedaviye uyum, sık hasta takibi ve ilaç yan etkileriyle mücadelenin kalıcı viral yanıt üzerine olan etkisinin değerlendirilmesi

• DOI: 10.17941/agd.41466
• Publication Date: 2007-12-01
• Authors: Serkan İpek; Laika Karabulut; Bilgivar Kaya; Arif Acar; Bilal Uğurlukişi; Yaşar Yoğun
• Keywords: Hasta; Hepatitis C; Antiviral Therapy

Background and Aim: Chronic hepatitis C patients who infected with genotype 1b consist the patient group which has lowest response to therapy. Infection is most prevalent in our country. In several studies, post-therapeutic sustained viral rate of chronic patients, 1b, 45-55 %. Our study was done evaluate effect compliance, frequent follow-up, struggle drug side effects genotype1b. 21 (17 female, 4 male) were taken this study. Material Method: Peginterferon alpha-2a ribavirin combination therapy given all for 48 weeks. Patients experienced close follow-up avoiding dose reductions as much possible. When necessary, minimal levels, then doses increased normal levels soon Results: group, early virological 95,2%, end treatment 85,7% 80,9%. Conclusion: According results, we think that frequeny side-effects will improve C.